DE112005001476A5 - Toxic substance-loaded dendritic cells for the treatment of renal cell carcinoma - Google Patents

Toxic substance-loaded dendritic cells for the treatment of renal cell carcinoma Download PDF

Info

Publication number
DE112005001476A5
DE112005001476A5 DE112005001476T DE112005001476T DE112005001476A5 DE 112005001476 A5 DE112005001476 A5 DE 112005001476A5 DE 112005001476 T DE112005001476 T DE 112005001476T DE 112005001476 T DE112005001476 T DE 112005001476T DE 112005001476 A5 DE112005001476 A5 DE 112005001476A5
Authority
DE
Germany
Prior art keywords
treatment
cell carcinoma
dendritic cells
renal cell
toxic substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112005001476T
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toximed GmbH
Original Assignee
Toximed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toximed GmbH filed Critical Toximed GmbH
Publication of DE112005001476A5 publication Critical patent/DE112005001476A5/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE112005001476T 2004-04-21 2005-04-20 Toxic substance-loaded dendritic cells for the treatment of renal cell carcinoma Withdrawn DE112005001476A5 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004019323A DE102004019323A1 (en) 2004-04-21 2004-04-21 Toxic substance-loaded dendritic cells for the treatment of renal cell carcinoma
DE102004019323.1 2004-04-21
PCT/DE2005/000719 WO2005103231A2 (en) 2004-04-21 2005-04-20 Dentritic cells charged with toxic substances in order to treat kidney cell carcinomas

Publications (1)

Publication Number Publication Date
DE112005001476A5 true DE112005001476A5 (en) 2007-05-24

Family

ID=34993192

Family Applications (2)

Application Number Title Priority Date Filing Date
DE102004019323A Withdrawn DE102004019323A1 (en) 2004-04-21 2004-04-21 Toxic substance-loaded dendritic cells for the treatment of renal cell carcinoma
DE112005001476T Withdrawn DE112005001476A5 (en) 2004-04-21 2005-04-20 Toxic substance-loaded dendritic cells for the treatment of renal cell carcinoma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE102004019323A Withdrawn DE102004019323A1 (en) 2004-04-21 2004-04-21 Toxic substance-loaded dendritic cells for the treatment of renal cell carcinoma

Country Status (2)

Country Link
DE (2) DE102004019323A1 (en)
WO (1) WO2005103231A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
DE19961141A1 (en) * 1999-12-17 2001-07-26 Mack Gerd R Pharmaceutical composition of spider venoms and their preparation and use for the treatment of tumor diseases
DE10024383B4 (en) * 2000-05-17 2005-07-21 Mack, Gerd R. Dendritic cells loaded with toxic substances
DE10024384A1 (en) * 2000-05-17 2001-11-29 Mack Gerd R Production of dendritic cells from spinal cord stem cells
WO2003006055A2 (en) * 2001-05-14 2003-01-23 Duotol Ab Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
WO2004053095A2 (en) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
JP2006518219A (en) * 2003-02-18 2006-08-10 マックスサイト インコーポレーティッド Method of loading antigen to cells by electroporation

Also Published As

Publication number Publication date
WO2005103231A2 (en) 2005-11-03
WO2005103231A3 (en) 2006-12-28
DE102004019323A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
ATE512663T1 (en) COMBINATION FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
ATE429218T1 (en) PINOLENEIC ACID FOR THE TREATMENT OF OBESITY
ATE434620T1 (en) DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES
DE602005023172D1 (en) HYDANTINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES
DE602005007717D1 (en) IMIDAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
DE602006018354D1 (en) METHOD FOR THE TREATMENT OF ABNORMAL CELL GROWTH
DK1786832T3 (en) TRANSPORT PROTEIN FOR INTRODUCING CHEMICAL COMPOUNDS IN NERV CELLS
DE602005005810D1 (en) USE OF SUBSTITUTED CHINOLIN DERIVATIVES FOR THE TREATMENT OF DRUG-RESISTANT MYCOBACTERIAL DISEASES
ATE369333T1 (en) SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
ATE375977T1 (en) SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES
DK3556866T3 (en) MUTATIONS OF THE PIK3CA GENE IN HUMAN CANCER
DE602006021154D1 (en) HYBRID BRANCHED POLYMER AND METHOD OF MANUFACTURING THEREOF
DE602005003581D1 (en) ELECTROLYSIS CELL
DK1701941T3 (en) Compounds for the Treatment of Diseases of Cell Proliferation
ATE527241T1 (en) PYRIDIAZINONE DERIVATIVES FOR THE TREATMENT OF TUMORS
DE602005007734D1 (en) PROCESS FOR THE PREPARATION OF TELMISARTAN
DE602005016141D1 (en) S-MIRTAZAPINE FOR THE TREATMENT OF HITZEWALLUNGEN
DE602006021192D1 (en) Visnadine for the treatment of scalp itching
ATE503752T1 (en) SULFAMIDE ALSENDOTHELIN RECEPTOR ANTAGONSITES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
MA28856B1 (en) RADIOSENSITIVE MATERIAL
DE602005013287D1 (en) COMPOSITION FOR THE TREATMENT OF LEATHER
ATE406465T1 (en) TANK BIOLEACHING PROCESS
DE112005001476A5 (en) Toxic substance-loaded dendritic cells for the treatment of renal cell carcinoma
ATE373477T1 (en) CCI-779 FOR THE TREATMENT OF MANLE CELL LYMPHOMA
DE602007003350D1 (en) TREATMENT OF POLYSILAZAN WASTE

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee